UNSPSC 51171633: Lubiprostone

This classification denotes a prostaglandin analogue with the molecular formula C20H32F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7662KG2R6K, chemically known as prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- but generally known as lubiprostone, which bears US NIH Compound Identifier 157920. European Medicines Agency schedules Lubiprostone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32077.

UNSPSC 51171633 Lubiprostone is a Commodity code that captures prescription pharmaceutical products for direct state and local government procurement, though recent activity under the code shows limited direct solicitation of lubiprostone itself. Instead, state and local buyers are acquiring lubiprostone and similar drugs through broader pharmaceutical supply agreements, cooperative purchasing frameworks, and pharmacy benefit programs that bundle multiple drug categories together. The kinds of issuing bodies soliciting under this code span state health and human services agencies, cooperative purchasing alliances serving multiple states and localities, and county-level criminal justice departments procuring pharmaceuticals for offender populations.

Recent opportunities reflect three distinct procurement models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and the remainder on administrative and technical compliance. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) to gather market intelligence about implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring vendors' capacity to enter direct contracts with state agencies outside traditional pharmacy benefit manager and group purchasing organization channels. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years, with three optional one-year renewal periods. Geographic spread includes Minnesota, Texas, and Oregon, with cooperative purchasing and state health agency activity driving the majority of recent volume.